The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mpn content recommended for you
Polycythemia vera (PV) is a Philadelphia-negative chronic myeloproliferative neoplasm (MPN) characterized by clonal expansion of erythrocytes.1 This leads to thrombotic complications and the risk of progression to post-PV myelofibrosis or blast phase.1
Currently, hydroxyurea (HU) is the most used cytoreductive therapy, but it is associated with poor responses and toxicity in a significant proportion of patients. Moreover, the predictors of a complete response (CR) with HU and its prognostic implications are yet to be defined.1 The impact of different types of suboptimal responses in patients switching to ruxolitinib (RUX) is also unclear.1
Palandri et al.1 recently published in Cancers, a real-world, retrospective study (PV-NET) identifying factors associated with CR during HU treatment, along with whether the type of HU responses would influence a patient’s decision to switch to RUX. The MPN Hub is pleased to summarize the key findings here.
This is an observational, retrospective cohort study across 22 hematologic centers. A total of 563 patients diagnosed with PV according to the World Health Organization 2016 definition between 1985 and 2000 and treated with HU for ≥12 months were included.
Table 1. Patient characteristics*
HU, hydroxyurea. *Adapted from Palandri, et al.1 †548 evaluable patients. ‡506 evaluable patients. |
|||
Characteristics |
Complete responders (n = 166) |
Poor responders (n = 397) |
p value |
---|---|---|---|
Median age (range), years |
70 (47–87) |
65 (21–89) |
<0.001 |
Sex, male (%) |
39.8 |
55.4 |
0.001 |
Median platelet count (range), ×109/L |
500 (159–1279) |
449 (138–1209) |
0.004 |
Median leukocyte count (range), ×109/L |
10 (3.3–30.3) |
10.1 (1–27.3) |
0.70 |
Median hemoglobin (range), g/dL |
|||
Male |
18.6 (15.8–23.6) |
18.7(12–23.4) |
0.59 |
Female |
17.8 (15.3–22) |
17.5 (13.2–21.9) |
0.09 |
Median hematocrit (range), % |
|||
Male |
55 (48.9–72.5) |
56.3 (38–73) |
0.70 |
Female |
54 (47.6–71.7) |
54.1 (39–72) |
0.99 |
Palpable spleen†, % |
15.8 |
39.4 |
<0.001 |
Pruritus, % |
17 |
39.9 |
<0.001 |
Thromboses pre-/at diagnosis, % |
23.5 |
25.7 |
0.58 |
Median HU dose‡ (range), g/d |
0.8 (0.2–2) |
0.5 (0.2–2) |
<0.001 |
Median HU dose ≥1 g/d, g/d |
49.6 |
26.17 |
<0.001 |
Figure 1. Response rates in patients treated with HU*
*Adapted from Palandri, et al.1
Figure 2. A) Response rates of patients who experienced a poor response to HU; B) Percentage of patients who experienced a poor response to HU who either remained on HU or switched to RUX*
HU-POOR, patients who experienced a poor response and remained on hydroxyurea; HU-RUX, patients who switched from hydroxyurea to ruxolitinib; NR, no response; PR, partial response.
*Adapted from Palandri, et al.1
Figure 3. Adverse events according to HU dose*
AE, adverse event; HU, hydroxyurea.
*Adapted from Palandri, et al.1
This real-world, retrospective cohort study highlights the importance of optimizing HU dosing. Although higher HU dosing achieves greater rates of CR it also increases the risk of TRAEs. In addition, the study also demonstrates the lack of an association between CR and reduced thrombotic risk. Therefore, HU dosing should be determined based on individual patient needs. Furthermore, a large proportion of stable poor responders continued HU treatment, emphasizing the need to improve overall therapeutic strategy. However, due to the retrospective nature, this study was limited by factors such as patient selection, uncontrolled drug prescription, inadequate recognition of poor response to HU, and inadequate drug compliance assessment.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content